Ginkgo Bioworks Holdings, Inc. (DNA) SEC Filings & Earnings Calls
EquiReason read 13 Ginkgo Bioworks Holdings, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-06 — Ginkgo reported a 48.5% YoY revenue decline in Q2 2026, with widened Adjusted EBITDA loss, driven by reduced customer programs..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 672.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
6 Aug 202610-QGinkgo reported a 48.5% YoY revenue decline in Q2 2026, with widened Adjusted EBITDA loss, driven by reduced customer programs.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $20M | -49% y/y |
| Net loss from continuing operations · Q2-2026 | $-57M | +8% y/y |
| Adjusted EBITDA · Q2-2026 | $-36M | +43% y/y |
| Cash and cash equivalents and marketable securities · 2026-06-30 | $302M |
Guidance
R&D and G&A expenses expected to remain consistent or decline in 2026 vs 2025
Management expects R&D and G&A to stabilize or decline, but revenue trajectory remains pressured.
Risks flagged
Customer concentration and program dependency
“Revenue decrease was primarily due to a decrease in the scope of services provided to a large enterprise customer in the agriculture industry and decrease in programs with large enterprise customers primarily in the pharmaceutical and biotechnology industries.”
Cash burn and liquidity runway
“We anticipate that our expenditures will exceed our revenue through at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q.” · word for word
Restricted cash from surety bond
“In April 2026, the Company was required to restrict $47.0 million of cash and cash equivalents to secure a surety bond of the same amount to fulfill its obligations under a contract with a U.S. Government National Laboratory related to the sale of RAC automation equipment.” · word for word
5 Aug 20268-K · 2.02Revenue $20M (-49% y/y); GAAP net loss from continuing operations $-57M (+8% y/y); Adjusted EBITDA $-36M (+44% y/y); Guidance: Expected total cash burn ($150)-($125) million in 2026earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $20M | -49% y/y |
| GAAP net loss from continuing operations · Q2-2026 | $-57M | +8% y/y |
| Adjusted EBITDA · Q2-2026 | $-36M | +44% y/y |
| Cash, cash equivalents and marketable securities · Q2-2026 | $302M |
Guidance
Expected total cash burn ($150)-($125) million in 2026
Reaffirmed cash burn guidance; no revenue guidance provided. Management tone positive on autonomous lab opportunity but near-term financials weak.
Risks flagged
Revenue decline of 48% YoY due to program rationalization; company is in restructuring mode with significant cash burn.
“The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities.” · word for word
Cash burn guidance of ($150)-($125)M for FY2026 implies continued negative cash flow; runway of $302M provides ~2 years of funding at current burn rate.
“Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.” · word for word
7 May 20268-K · 2.02Revenue $19M (-49% y/y); GAAP net loss from continuing operations $-76.00; Adjusted EBITDA $-42.00; Guidance: Total cash burn $(150)-$(125) million in 2026earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $19M | -49% y/y |
| GAAP net loss from continuing operations · Q1-2026 | $-76.00 | |
| Adjusted EBITDA · Q1-2026 | $-42.00 | |
| Cash, cash equivalents and marketable securities · Q1-2026 | $373M |
Guidance
Total cash burn $(150)-$(125) million in 2026
Reaffirmed FY2026 cash burn guidance; management optimistic about autonomous lab scaling.
Risks flagged
Revenue decline due to program rationalization and divestiture; ongoing restructuring.
“The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities.” · word for word
7 May 202610-QGinkgo reported a 49% YoY revenue decline in Q1 2026, driven by non-cash revenue release and reduced customer scope, though operating loss narrowed.earningsopen
Figures in the filing · each found in the filing text
| Revenue · continuing operations · Q1-2026 | $19M | -49% y/y |
| Net loss from continuing operations · continuing operations · Q1-2026 | $-76M | +9% y/y |
| Adjusted EBITDA · continuing operations · Q1-2026 | $-42M | +5% y/y |
| Cash and cash equivalents and marketable securities · 2026-03-31 | $374M |
Risks flagged
Customer concentration risk
“a decrease in the scope of services provided to a large enterprise customer in the agriculture industry” · word for word
Cash restriction risk
“In April 2026, the Company was required to restrict $47.0 million of cash and cash equivalents to secure a surety bond... expected to be restricted until 2029.” · word for word
29 Apr 2026DEF 14AProxy statement for 2026 annual meeting; executive compensation tied to cash flow reduction; board restructuring; no material operational or financial event.open
Figures in the filing · each found in the filing text
| Adjusted Cash Flow · FY2025 | $-157M | |
| Net Income (Loss) · FY2025 | $-313M | |
| Total Shareholder Return (TSR) · FY2025 | $1.71 | |
| Peer Group TSR · FY2025 | $92.84 |
Risks flagged
Founder control risk
“All Directors and Executive Officers of Ginkgo as a Group (8 individuals) 1,748,360 3.3% 6,138,795 68.5% 44.2%” · word for word
Cash burn risk
“Adjusted Cash Flow ($ Millions) (i) 2025: (157)”
7 Apr 20268-K · 2.01Completed an acquisition or disposition of significant assets; filed financial statements and exhibits with this reportacquisitionopen
Risks flagged
Loss of biosecurity segment revenue and operations
“Substantially all of the Company’s operations comprising its Biosecurity segment were divested.” · word for word
27 Feb 20268-K · 1.01Ginkgo Bioworks contributes its Biosecurity segment to Tower Biosecurity in exchange for ~20% equity stake; transaction expected H1 2026.being acquiredopen
Risks flagged
Execution risk in closing the transaction and potential loss of key segment revenue.
“Transaction subject to customary closing conditions; forward-looking statements highlight risks including ability to consummate in timely manner.”
26 Feb 20268-K · 2.02Total Revenue $170M (-25% y/y); Cell Engineering Revenue $133M (-24% y/y); Biosecurity Revenue $37M (-30% y/y)earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $170M | -25% y/y |
| Cell Engineering Revenue · Cell Engineering · FY2025 | $133M | -24% y/y |
| Biosecurity Revenue · Biosecurity · FY2025 | $37M | -30% y/y |
| GAAP Net Loss · FY2025 | $-313M | +43% y/y |
| Adjusted EBITDA · FY2025 | $-167M | +43% y/y |
| Cash, Cash Equivalents and Marketable Securities · Q4-2025 | $423M |
Risks flagged
Revenue decline across both segments; restructuring and divestiture signal ongoing business model transition
“Total revenue down 25% YoY; Cell Engineering down 24%; Biosecurity down 30%; divesting biosecurity business”
26 Feb 202610-KAnnual report (10-K) filed with full financial statements, highlighting continued losses and restructuring.open
Figures in the filing · each found in the filing text
| accumulated deficit · FY2025 | $6.20B | |
| restructuring costs · FY2025 | $11M | |
| restructuring costs · FY2024 | $19M |
Risks flagged
Going concern risk due to accumulated losses
“We have incurred significant operating losses since our inception. As of December 31, 2025, we had an accumulated deficit of approximately $6.2 billion.” · word for word
Customer concentration risk
“For the year ended December 31, 2025, one customer in the Cell Engineering segment accounted for 15% of the Company’s total revenue, while one customer in the Biosecurity segment accounted for 12% of the Company’s total revenue.” · word for word
Supply chain dependency on single-source suppliers
“We depend on a limited number of suppliers, some of which are single-source suppliers, and contract manufacturers for critical supplies, equipment, and services for research, development, and manufacturing of our products and processes.” · word for word
23 Dec 20258-K · 5.02, 8.01Reported the departure of a director or principal officer (CEO/CFO change); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Leadership transition risk as COO duties are reassigned, but founder remains in key role.
“Dr. Shetty will transition her Chief Operating Officer duties to Jennifer Wipf and Dr. Jason Kelly.”
6 Nov 20258-K · 2.02Ginkgo Bioworks reported Q3 2025 total revenue of $39M, down 56% YoY (or 11% excluding prior year non-cash revenue), GAAP net loss of $(81)M, and Adjusted EBITDA of $(56)M. Reaffirmed FY2025 total revenue guidance of $167-$187M.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $39M | -56% y/y |
| Cell Engineering revenue · Cell Engineering · Q3-2025 | $29M | -61% y/y |
| Biosecurity revenue · Biosecurity · Q3-2025 | $9M | -36% y/y |
| GAAP net loss · Q3-2025 | $-81M | +45% y/y |
| Adjusted EBITDA · Q3-2025 | $-56M | +180% y/y |
| Cash, cash equivalents and marketable securities · 2025-09-30 | $462M |
Guidance
FY2025 total revenue $167-$187M; Cell Engineering $117-$137M; Biosecurity at least $40M
Management reaffirmed full-year guidance despite weak Q3, citing AI strategy and new contracts.
Risks flagged
Revenue decline and widening losses indicate operational challenges.
“Total revenue down 56% YoY; GAAP net loss increased to $(81)M from $(56)M.”
Dependence on non-recurring revenue items (deferred revenue release) distorts comparability.
“Prior year included $45M non-cash revenue from mutual termination of a customer agreement.”
6 Nov 202510-QGinkgo reported Q3 2025 results with a 56% YoY revenue decline, driven by the loss of a large related-party Cell Engineering contract, and continued cash burn.earningsopen
Figures in the filing · each found in the filing text
| Cell Engineering revenue · Cell Engineering · Q3-2025 | $29M | -61% y/y |
| Biosecurity revenue · Biosecurity · Q3-2025 | $9M | -32% y/y |
| Total revenue · Q3-2025 | $39M | -56% y/y |
| Net loss · Q3-2025 | $-81M | +43% y/y |
| Operating cash flow · 9M-2025 | $-123M | -56% y/y |
| Restructuring charges · 9M-2025 | $11M | -47% y/y |
Risks flagged
Customer concentration and related-party revenue decline
“Includes related party revenue of zero and $46,659 for the three months ended September 30, 2025 and 2024, respectively.” · word for word
Cash burn and going concern risk
“Net cash used in operating activities $123,381 thousand for 9M 2025; cash and cash equivalents $111,065 thousand as of Sep 2025.”
Restructuring execution risk
“The actual timing for subleasing unused or underutilized facilities is expected to extend into 2026 or may not occur prior to termination of such lease.” · word for word
Government contract awards
federal awards · contract value, often multi-year| Date | Agency | Value | What for |
|---|---|---|---|
| 2026-03-30 | Centers for Disease Control and Preventi | $21M | TRAVELER-BASED GENOMIC SURVEILLANCE PROGRAM |
Ginkgo Bioworks Holdings, Inc. — questions
- What did Ginkgo Bioworks Holdings, Inc. file recently?
- 13 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-06 — Ginkgo reported a 48.5% YoY revenue decline in Q2 2026, with widened Adjusted EBITDA loss, driven by reduced customer programs.
Every figure on this page comes from Ginkgo Bioworks Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.